2-Methoxy-4-methyl-pentane | 89045-04-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methoxy-4-methyl-pentane
• 英文别名: 2-Methoxy-4-methylpentane
• CAS: 89045-04-5
• 化学式: C₇H₁₆O
• 分子量: 116.203
• InChiKey: XOOBTEUBXZXNKK-UHFFFAOYSA-N

物化性质

• 保留指数：
  734.6

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-甲基-2-戊醇 、 碘甲烷 在 sodium hydride 作用下， 生成 2-Methoxy-4-methyl-pentane
  参考文献：
  名称：

  酸诱导的13 C核磁共振醚和酯碳原子的化学位移变化

  摘要：

  溶解在四氯甲烷中的醚的13 C Nmr化学位移可通过添加三氟乙酸来置换。位移是由酸与底物氧原子和烷基残基的独立相互作用导致的。依赖于结构的和立体选择性的移位变化可用于信号分配，结构确定，构象分析，评估酯的快速互变构象异构体的分布以及估算醚的相对碱性。

  DOI：

  10.1039/p29830001609

文献信息

• CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP
  申请人：Kimura Tomio

  公开号：US20090306059A1

  公开（公告）日：2009-12-10

  A compound having the general formula (I), pharmacologically acceptable salts thereof or prodrugs thereof: [wherein R 1 represents a hydrogen atom, a C1-C6 alkyl group which may be substituted, a C3-C6 cycloalkyl group which may be substituted, a C1-C6 alkoxy group which may be substituted or a C6-C10 aryl group which may be substituted; R 2 represents a hydrogen atom, a halogen atom, a carboxy group, a C2-C7 alkoxycarbonyl group, a carbamoyl group, a cyano group, a C1-C6 alkyl group, a halogeno C1-C6 alkyl group, a C1-C6 alkyl group substituted by a heteroaryl group, a C1-C6 alkoxy group, a halogeno C1-C6 alkoxy group, a hydroxy C1-C6 alkyl group, a C2-C12 alkoxyalkyl group, a formyl group, a C2-C7 alkanoyl group, a C4-C7 cycloalkylcarbonyl group, a C2-C7 alkylcarbamoyl group, a di(C1-C6 alkyl)carbamoyl group, a group of formula R 4 —CO—CR 5 R 6 —(CH 2 ) m —, a group of formula R 7 —CO—(CH 2 ) l —N(R 8 )— or a sulfamoyl C1-C6 alkyl group; R 3 represents a substituted C1-C6 alkyl group, a heterocyclyl group or a heterocyclyl group substituted with 1 to 5 substituents; X 1 , X 2 , X 3 , X 4 and X 5 each independently represents a hydrogen atom, a halogen atom, an amino group, a carboxy group, a carbamoyl group, a cyano group, a nitro group, a C1-C6 alkyl group, a halogeno C1-C6 alkyl group, a C1-C6 alkoxy group, or a halogeno C1-C6 alkoxy group; and n represents an integer of 0 to 2].

  具有通式（I）的化合物，其药学上可接受的盐或前药： [其中R1代表氢原子，可能被取代的C1-C6烷基，可能被取代的C3-C6环烷基，可能被取代的C1-C6烷氧基或可能被取代的C6-C10芳基； R2代表氢原子，卤原子，羧基，C2-C7烷氧羰基，氨基甲酰基，氰基，C1-C6烷基，卤代C1-C6烷基，被杂环芳基取代的C1-C6烷基，C1-C6烷氧基，卤代C1-C6烷氧基，羟基C1-C6烷基，C2-C12烷氧基烷基，甲酰基，C2-C7烷酰基，C4-C7环烷基羰基，C2-C7烷基氨基甲酰基，二(C1-C6烷基)氨基甲酰基，通式R4—CO—CR5R6—(CH2)m—的基团，通式R7—CO—(CH2)l—N(R8)—或磺胺基C1-C6烷基； R3代表取代的C1-C6烷基，杂环烷基或带有1至5个取代基的取代的杂环烷基； X1、X2、X3、X4和X5分别独立地代表氢原子，卤原子，氨基，羧基，氨基甲酰基，氰基，硝基，C1-C6烷基，卤代C1-C6烷基，C1-C6烷氧基或卤代C1-C6烷氧基；以及 n代表0至2的整数。
• [EN] 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY<br/>[FR] DÉRIVÉS DE 2-PHÉNYL-3H-IMIDAZO[4,5-B]PYRIDINE UTILISÉS COMME INHIBITEURS DE L'ACTIVITÉ DE LA TYROSINE KINASE DE MAMMIFÈRE ROR1
  申请人：KANCERA AB

  公开号：WO2016124553A1

  公开（公告）日：2016-08-11

  A compound of formula (I´) or (I´´) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

  化合物的化学式（I´）或（I´´）或其药学上可接受的盐。该化合物是哺乳动物激酶酶活性的抑制剂，包括ROR1酪氨酸激酶活性，并可用于治疗与该活性相关的疾病。
• Method for the production of beta-ketonitriles
  申请人：Vogelbacher Uwe Josef

  公开号：US20100105903A1

  公开（公告）日：2010-04-29

  The present invention relates to a process for preparing β-ketonitriles of the general formula I in which R 1 is, inter alia, C 1 -C 12 -alkyl, C 2 -C 12 -alkenyl, C 2 -C 12 -alkinyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl, phenoxy-C 1 -C 4 -alkyl or benzyloxy-C 1 -C 4 -alkyl; R 2 is, inter alia, hydrogen, C 1 -C 12 -alkyl, C 2 -C 12 -alkenyl, C 2 -C 12 -alkinyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, phenyl, phenyl-C 1 -C 4 -alkyl, phenoxy-C 1 -C 4 -alkyl or benzyloxy-C 1 -C 4 -alkyl, which comprises reacting a nitrile of the formula II in which R 1 has one of the meanings given above with a carboxylic ester of the formula III in which R 2 has one of the meanings given above and R 3 is C 1 -C 12 -alkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl, phenoxy-C 1 -C 4 -alkyl or benzyloxy-C 1 -C 4 -alkyl, where the reaction is carried out in the presence of a potassium alkoxide and at least 80% of the nitrile of the formula II are added to the reaction under reaction conditions.

  本发明涉及一种制备一般式I的β-酮腈的方法，其中R1是C1-C12-烷基、C2-C12-烯基、C2-C12-炔基、C3-C8-环烷基、C3-C8-环烷基-C1-C4-烷基、苯基-C1-C4-烷基、苯氧基-C1-C4-烷基或苄氧基-C1-C4-烷基；R2是氢、C1-C12-烷基、C2-C12-烯基、C2-C12-炔基、C3-C8-环烷基、C3-C8-环烷基-C1-C4-烷基、苯基、苯基-C1-C4-烷基、苯氧基-C1-C4-烷基或苄氧基-C1-C4-烷基。该方法包括将具有上述给定含义之一的一般式II的腈与具有上述给定含义之一的一般式III的羧酸酯反应，其中R3是C1-C12-烷基、C1-C4-烷氧基-C1-C4-烷基、C3-C8-环烷基、C3-C8-环烷基-C1-C4-烷基、苯基-C1-C4-烷基、苯氧基-C1-C4-烷基或苄氧基-C1-C4-烷基，在存在钾醇和至少80%的一般式II的腈被加入到反应中，并在反应条件下进行。
• SELF-ASSEMBLED NANOSTRUCTURES
  申请人：MAKEIFF Darren Andrew

  公开号：US20110282072A1

  公开（公告）日：2011-11-17

  An alkylated benzimidazolone compound of the formula: wherein at least one of R 1 to R 4 is X—R c , where X represents a linking group, and R a , R b , and R c independently represents substituted or unsubstituted alkyl groups, provided that at least one of R a and R b represents H. The present disclosure provides alkylated benzimidazolone compounds and self-assembled nanostructures formed from alkylated benzimidazolone compounds.

  一种具有以下结构的烷基化苯并咪唑酮化合物：其中R1至R4中至少有一个为X—Rc，其中X代表连接基团，而Ra、Rb和Rc分别代表取代或未取代的烷基基团，但至少有一个为H。本公开提供了烷基化苯并咪唑酮化合物和由烷基化苯并咪唑酮化合物形成的自组装纳米结构。
• Oligosaccharide derivative
  申请人：Honda Takeshi

  公开号：US20060025350A1

  公开（公告）日：2006-02-02

  Compounds having the formula (I): wherein A represents a group such as a cyclic group, R 1 and R 2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

  具有化学式（I）的化合物：其中A代表环状基团，R1和R2代表烷基或羟甲基等基团，n代表1或2，或其药学上可接受的盐或酯具有卓越的活性和稳定性，并且可用于治疗和/或预防糖尿病等疾病。